Getinge, the Swedish medical technology company, projects organic sales growth of 3-5% in 2026. This comes after a 4.9% increase in 2025. The firm is also proposing a higher dividend of SEK 4.75 per share, up from SEK 4.60. Despite geopolitical uncertainty, the company appears confident in its outlook. Full-year net sales matched forecasts.

Getinge's adjusted EBITA remained relatively stable at SEK 4.88 billion. Currency movements and tariffs impacted results, reducing them by over SEK 1 billion. The fourth quarter showed a strong performance, with a 1.2% organic sales increase. Demand for consumables and strong sales in Transplant Care contributed to the company's positive results.

Looking ahead, Getinge plans to launch new products, including the Automatiq system. Deliveries of the Cardiosave intra-aortic balloon pump are expected in Q2 2026. The medical device market is competitive, and Getinge's performance is crucial for investors. The company's ability to navigate economic headwinds is key.